Study: NCT04746183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CST-2: EIDD-2801
Description: CST-2 Phase Ib: EIDD-2801 will be administered orally, twice daily (BID) for 10 doses (5 or 6 days). The starting dose will be established based on safety and pharmacokinetics from the EIDD-2801-1001-US/UK study, and dose escalations may occur as described in this CST.~Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CST-2: EIDD-2801
Description: CST-2 Phase Ib: EIDD-2801 will be administered orally, twice daily (BID) for 10 doses (5 or 6 days). The starting dose will be established based on safety and pharmacokinetics from the EIDD-2801-1001-US/UK study, and dose escalations may occur as described in this CST.~Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CST-2: Placebo
Description: CST-2 Phase II: Placebo will be administered orally, twice daily (BID) for 10 doses (5 or 6 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: CST3A \& CST3B Phase I: Nitazoxanide will be administered orally, initially twice daily (BID) for 14 doses (7 days). The starting dose will be 1500mg BID based on existing dose information, but dose adaptations may occur.~Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: CST3A \& CST3B Phase I: Nitazoxanide will be administered orally, initially twice daily (BID) for 14 doses (7 days). The starting dose will be 1500mg BID based on existing dose information, but dose adaptations may occur.~Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VIR-7832
Description: CST-5: Phase I, Single doses of VIR-7832 will be administered by intravenous (IV) infusion over 1 hour. The starting dose will be 50 mg, and dose escalations of 150 and 500 mg are anticipated, with escalation guided by emerging safety data and decision by the SRC.~Phase II: As per Phase I, with the dose determined by the recommended phase II dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-7832
Description: CST-5: Phase I, Single doses of VIR-7832 will be administered by intravenous (IV) infusion over 1 hour. The starting dose will be 50 mg, and dose escalations of 150 and 500 mg are anticipated, with escalation guided by emerging safety data and decision by the SRC.~Phase II: As per Phase I, with the dose determined by the recommended phase II dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VIR-7831
Description: CST-5 Phase II: A 500 mg dose of VIR-7831 will also be given by IV infusion over 1 hour.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CST-5: Placebo
Description: CST-5 Phase 1, Phase II: Placebo given by intravenous infusion over 1 hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CST-5: Placebo
Description: CST-5 Phase 1, Phase II: Placebo given by intravenous infusion over 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: CST-6: Multiple doses of IV Favipiravir will be administered by intravenous (IV) infusion over 1 hour. Dosing regimen will be every 12 hours for 7 days duration. The starting dose will be 600mg (BID), and dose escalations to 1200mg (BID), 1800mg (BID) and 2400mg (BID) are anticipated as well as a de-escalation dose of 300mg (BID) if necessary, with de-escalation and escalation guided by emerging safety data and decision by the Safety Review Committee (SRC).